Approaches to Understanding and Addressing Treatment-resistant Depression: a Scoping Review

Overview

Journal Depress Res Treat

Publisher Wiley

Date 2012 May 10

PMID 22570778

Citations 8

Authors

Emily Jenkins

Elliot M Goldner

Affiliations

Soon will be listed here.

Abstract

Treatment-resistant depression is associated with significant disability and, due to its high prevalence, results in substantive economic and societal burden at a population level. The objective of this study is to synthesize extant literature on approaches currently being applied to understand and address this condition. It is hoped that the findings can be used to inform practitioners and guide future research. A scoping review of the scientific literature was conducted with findings categorized and charted by underlying research paradigm. Currently, the vast majority of research stems from a biological paradigm (81%). Research on treatment-resistant depression would benefit from a broadened field of study. Given that multiple etiological mechanisms likely contribute to treatment-resistant depression and current efforts at prevention and treatment have substantial room for improvement, an expanded research agenda could more effectively address this significant public health issue.

Citing Articles

The role of NMDARs in the anesthetic and antidepressant effects of ketamine.

Zhou L, Duan J CNS Neurosci Ther. 2023; 30(4):e14464.

PMID: 37680076 PMC: 11017467. DOI: 10.1111/cns.14464.

Ketamine Evolving Clinical Roles and Potential Effects with Cognitive, Motor and Driving Ability.

Edinoff A, Sall S, Koontz C, Williams A, Drumgo D, Mouhaffel A Neurol Int. 2023; 15(1):352-361.

PMID: 36976666 PMC: 10054038. DOI: 10.3390/neurolint15010023.

Carveol Promotes Nrf2 Contribution in Depressive Disorders through an Anti-inflammatory Mechanism.

Muhammad A, Hao L, Al Kury L, Ur Rehman N, Alvi A, Badshah H Oxid Med Cell Longev. 2022; 2022:4509204.

PMID: 35295720 PMC: 8920705. DOI: 10.1155/2022/4509204.

The MAKE Biomarker Discovery for Enhancing anTidepressant Treatment Effect and Response (MAKE BETTER) Study: Design and Methodology.

Kang H, Kim J, Kim S, Kim S, Shin H, Shin M Psychiatry Investig. 2018; 15(5):538-545.

PMID: 29614851 PMC: 5975999. DOI: 10.30773/pi.2017.10.2.

Propentofylline Prevents Sickness Behavior and Depressive-Like Behavior Induced by Lipopolysaccharide in Rats via Neuroinflammatory Pathway.

Moraes M, Galvao M, Cabral D, Coelho C, Queiroz-Hazarbassanov N, Martins M PLoS One. 2017; 12(1):e0169446.

PMID: 28056040 PMC: 5215944. DOI: 10.1371/journal.pone.0169446.

References

Parikh S, Lam R . Clinical guidelines for the treatment of depressive disorders, I. Definitions, prevalence, and health burden. Can J Psychiatry. 2001; 46 Suppl 1:13S-20S. View

Lam R, Chan P, Wilkins-Ho M, Yatham L . Repetitive transcranial magnetic stimulation for treatment-resistant depression: a systematic review and metaanalysis. Can J Psychiatry. 2008; 53(9):621-31. DOI: 10.1177/070674370805300909. View

Malhi G, Parker G, Crawford J, Wilhelm K, Mitchell P . Treatment-resistant depression: resistant to definition?. Acta Psychiatr Scand. 2005; 112(4):302-9. DOI: 10.1111/j.1600-0447.2005.00602.x. View

Carpenter L, Bayat L, Moreno F, Kling M, Price L, Tyrka A . Decreased cerebrospinal fluid concentrations of substance P in treatment-resistant depression and lack of alteration after acute adjunct vagus nerve stimulation therapy. Psychiatry Res. 2007; 157(1-3):123-9. DOI: 10.1016/j.psychres.2007.04.016. View

Carvalho A, Cavalcante J, Castelo M, Lima M . Augmentation strategies for treatment-resistant depression: a literature review. J Clin Pharm Ther. 2007; 32(5):415-28. DOI: 10.1111/j.1365-2710.2007.00846.x. View

Judd L, Akiskal H, Maser J, Zeller P, Endicott J, Coryell W . Major depressive disorder: a prospective study of residual subthreshold depressive symptoms as predictor of rapid relapse. J Affect Disord. 1998; 50(2-3):97-108. DOI: 10.1016/s0165-0327(98)00138-4. View

Burke M, Husain M . Concomitant use of vagus nerve stimulation and electroconvulsive therapy for treatment-resistant depression. J ECT. 2006; 22(3):218-22. DOI: 10.1097/01.yct.0000230364.04240.52. View

Ruhe H, van Rooijen G, Spijker J, Peeters F, Schene A . Staging methods for treatment resistant depression. A systematic review. J Affect Disord. 2011; 137(1-3):35-45. DOI: 10.1016/j.jad.2011.02.020. View

Keller M . Issues in treatment-resistant depression. J Clin Psychiatry. 2005; 66 Suppl 8:5-12. View

10.

Fava M . Diagnosis and definition of treatment-resistant depression. Biol Psychiatry. 2003; 53(8):649-59. DOI: 10.1016/s0006-3223(03)00231-2. View

11.

Carvalho L, Garner B, Dew T, Fazakerley H, Pariante C . Antidepressants, but not antipsychotics, modulate GR function in human whole blood: an insight into molecular mechanisms. Eur Neuropsychopharmacol. 2010; 20(6):379-87. PMC: 2982744. DOI: 10.1016/j.euroneuro.2010.02.006. View

12.

COHEN C . The biomedicalization of psychiatry: a critical overview. Community Ment Health J. 1993; 29(6):509-21. DOI: 10.1007/BF00754260. View

13.

Greenberg P, Corey-Lisle P, Birnbaum H, Marynchenko M, Claxton A . Economic implications of treatment-resistant depression among employees. Pharmacoeconomics. 2004; 22(6):363-73. DOI: 10.2165/00019053-200422060-00003. View

14.

Fekadu A, Wooderson S, Donaldson C, Markopoulou K, Masterson B, Poon L . A multidimensional tool to quantify treatment resistance in depression: the Maudsley staging method. J Clin Psychiatry. 2009; 70(2):177-84. DOI: 10.4088/jcp.08m04309. View

15.

Sackeim H . The definition and meaning of treatment-resistant depression. J Clin Psychiatry. 2001; 62 Suppl 16:10-7. View

16.

Matsunaga M, Okamoto Y, Suzuki S, Kinoshita A, Yoshimura S, Yoshino A . Psychosocial functioning in patients with Treatment-Resistant Depression after group cognitive behavioral therapy. BMC Psychiatry. 2010; 10:22. PMC: 2856539. DOI: 10.1186/1471-244X-10-22. View

17.

Kito S, Hasegawa T, Fujita K, Koga Y . Changes in hypothalamic-pituitary-thyroid axis following successful treatment with low-frequency right prefrontal transcranial magnetic stimulation in treatment-resistant depression. Psychiatry Res. 2009; 175(1-2):74-7. DOI: 10.1016/j.psychres.2008.10.002. View

18.

Schramm E, Schneider D, Zobel I, van Calker D, Dykierek P, Kech S . Efficacy of Interpersonal Psychotherapy plus pharmacotherapy in chronically depressed inpatients. J Affect Disord. 2007; 109(1-2):65-73. DOI: 10.1016/j.jad.2007.10.013. View

19.

Kito S, Fujita K, Koga Y . Changes in regional cerebral blood flow after repetitive transcranial magnetic stimulation of the left dorsolateral prefrontal cortex in treatment-resistant depression. J Neuropsychiatry Clin Neurosci. 2008; 20(1):74-80. DOI: 10.1176/jnp.2008.20.1.74. View

20.

Berlim M, Fleck M, Turecki G . Current trends in the assessment and somatic treatment of resistant/refractory major depression: an overview. Ann Med. 2008; 40(2):149-59. DOI: 10.1080/07853890701769728. View